Intercellular traffic of human immunodeficiency virus type 1 transactivator protein defined by monoclonal antibodies  by Demirhan, Ilhan et al.
Intercellular tra⁄c of human immunode¢ciency virus type 1
transactivator protein de¢ned by monoclonal antibodies
Ilhan Demirhan, Angelika Chandra, Oliver Hasselmayer, Prakash Chandra*
Gustav-Embden Center of Biological Chemistry, Department of Molecular Biology, Frankfurt University Medical School, Theodor-Stern Kai 7,
D-60590 Frankfurt, Germany
Received 13 January 1999
Abstract Monoclonal antibodies (mAbs) directed against the
amino-terminal region (N-terminal sequence 2^19) of transacti-
vator protein (tat) of HIV-1 have been shown to inhibit
intercellular transactivation mediated by the extracellular tat
protein. The intracellular transactivation was not significantly
affected by anti-tat mAbs. The specificity of anti-tat mAbs in
abolishing the transactivating potential of extracellular tat is
documented by studies with mAbs to HIV-1 reverse transcrip-
tase, or to a human mammary cancer protein. None of these
antibodies showed any inhibitory effect on intercellular transac-
tivation. Specific interaction of anti-tat IgG with tat protein
expressed in Jurkat cells is further supported by experiments on
immunoblotting. Extracellular tat is responsible for signals which
induce a variety of biological responses in HIV-infected cells, as
well as in uninfected cells. The fact that anti-tat mAbs can
abolish the intercellular traffic of tat protein offers a unique
strategy in the development of vaccines against AIDS.
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1. Introduction
The tat protein encoded by the human immunode¢ciency
virus type 1 (HIV-1) is a potent trans-activator of gene ex-
pression from the viral long terminal repeat (LTR). The do-
mains that are essential for trans-activation, a Pro-xaa3-Pro
triad, a cysteine-rich metal binding sequence motif, and a
cluster of basic residues, are present within the N-terminal
57 residues of tat protein. In recent years, additional functions
for tat have been detected which are attributed to its extra-
cellular release from infected cells. Tat uptake not only enhan-
ces HIV-1 transcription in infected cells, it also a¡ects a range
of host cell genes in both infected and uninfected cells. These
include activation of tumor necrosis factor (TNF), interleu-
kin-6 (IL-6), CD-4, IL-2, IL-2RK, IL-10, transforming growth
factor-L1 (TGF-L1), and CD95 ligand [1^5].
In this communication we have compared the intracellular
and intercellular transactivation mediated by the tat protein.
Intracellular transactivation designates the phenomenon
where a single cell population was cotransfected with plasmids
containing tat-expressing construct and the HIV-1 LTR con-
struct hybridized to the chloramphenicol acetyltransferase
(CAT) gene. Intercellular transactivation was studied by
transfecting two cell populations separately by either of these
plasmids, and then co-cultivating the two cell populations
together. We found that addition of tat IgG to the culture
medium abolishes intercellular transactivation, but has little
e¡ect on intracellular transactivation. This is attributed to the
interdiction of extracellular tat by the monoclonal antibodies
(mAbs). This is further supported by the fact that antibodies
directed against HIV-1 reverse transcriptase or speci¢c to a
human mammary cancer protein failed to in£uence the inter-
cellular transactivation potential of tat protein. Speci¢c inter-
action of anti-tat IgG to tat protein expressed in Jurkat cells is
also documented in experiments with immunoblotting. The
studies o¡er tat protein as a unique target for active and
passive vaccination against AIDS.
2. Materials and methods
2.1. Chemicals
The culture medium (RPMI 1640) and fetal calf serum were sup-
plied by Gibco (Eggenstein). [14C]Acetyl-CoA (4 mCi/mmol) was ob-
tained from NEN/Dupont (Dreieich). All other reagents were analyt-
ical grade of high purity obtained from Merck (Darmstadt) or Serva
(Heidelberg).
2.2. Plasmids
The tat gene (clone 1) was cloned by way of cDNA cloning, using
poly(A)-selected RNA from HIV-1 (BH 10)-infected cells [6,7]. The
HIV-1 LTR-CAT construct was obtained by inserting clone 15 DNA
into pSV0-CAT at the HindIII site [6,8], and the resulting plasmid was
termed pC15CAT. The plasmid pCV1 was obtained by inserting viral
cDNA containing the tat gene (clone 1) into the mammalian expres-
sion vector pCV which contains duplicated SV40 origins of replication
(ori), adenovirus major late promoter, splice sites from adenovirus
and mouse immunoglobulin genes, mouse dihydrofolate reductase
cDNA, and SV40 polyadenylation signal. We are grateful to Dr.
S.K. Arya for the preparation of these plasmids.
2.3. Transfection and CAT assay
Jurkat cells (1U107) were washed with serum-free medium and
incubated at 37‡C for 1 h in 1 ml serum-free medium containing 50
mM Tris-HCl (pH 7.3), DEAE dextran (Mr 500 000, 250 Wg/ml) and
15 Wg of each plasmid DNA, pCV 1 and pC15CAT. The cells were
then washed with RPMI medium (without serum) and incubated in 10
ml serum-containing medium at 37‡C. At this time, the test com-
pounds were added at the desired concentrations in parallel batches.
44 h after the incubation, cells were washed with phosphate bu¡ered
saline and suspended in 80 Wl of 0.25 M Tris-HCl (pH 7.8), and
cellular extracts were prepared by three cycles of freezing (in liquid
nitrogen) and thawing (37‡C). All cellular extracts were adjusted to
equal protein concentration and heated for 15 min at 65‡C to inacti-
vate deacetylases in the extract. For CAT assays, 30 Wl of the cell
extract was mixed with 20 Wl of 100 mM Tris-HCl (pH 7.8) in a 6 ml
glass scintillation vial. The vial was transferred to a water bath set at
37‡C and 200 Wl of a freshly prepared CAT reaction mixture (100 Wl
of 0.25 M Tris-HCl, pH 7.8, 50 Wl of 5 mM chloramphenicol, 10 Wl
[14C]acetyl-CoA, 0.1 WCi, and 40 Wl water) was added. To this mix-
ture, 5 ml of a water-immiscible scintillation £uid (Econo£uor, NEN/
Dupont) was carefully overlaid and incubated at 37‡C for 4 h. All
transfections were performed in triplicate for each set of experiments.
2.4. Monoclonal antibodies
BALB/c mice were immunized subcutaneously with 100 Wg of a
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recombinant tat protein expressed in Escherichia coli, emulsi¢ed in
Freund’s complete adjuvant, followed by three inoculations of 50 Wg
tat protein in incomplete Freund’s adjuvant at 3 week intervals.
Eighty-four hours after the last booster, splenic lymphocytes (approx-
imately 108 cells) were mixed with P3-X63-Ag8.653 mouse myeloma
cells (4U107 cells). The fusion procedure, cell culturing and cloning of
hybridomas were similar to the procedures described by Galfre et al.
[9]. Hybridoma cultures were screened for antibodies to tat protein by
enzyme-linked immunosorbent assay (ELISA), using a direct antigen-
coated plate method. One of the clones, designated C3.2D7, was
found to secrete antibodies reacting with the N-terminal sequence
(2^19) of tat protein. The sequential tat peptides were synthesized
by the solid-phase method on a fully automated peptide synthesizer
(Beckman, 990) with PAM resin. Compositional analysis was per-
formed on the peptides to con¢rm primary structure. For preparing
ascites £uid containing anti-tat mAb cells from clone C3.2D7 (1U107
cells) were injected into pristane-primed BALB/c mice, and ascites was
collected (2^6 ml per mouse) 2 weeks later. Further puri¢cation was
carried out using protein G-Sepharose columns.
Hybridoma clones secreting mAb to HIV-1 reverse transcriptase
were generated by the same procedure, and the details have been
described elsewhere [10,11]. Hybridoma clones secreting antibodies
to a 80 kDa protein from human mammary carcinoma cells (T47D)
were generated by a similar procedure. The puri¢cation of this protein
has been described elsewhere (A. Chandra, G. Bosma and P. Chan-
dra, in preparation).
2.5. Immunoblotting of tat protein
Jurkat cells were transfected with a tat-expressing vector pCV1;
non-transfected cells served as control. The transfection procedure
and the preparation of cell lysates is described in Section 2.3. Lysates
from pCV1-transfected and non-transfected cells were fractionated by
SDS-polyacrylamide slab gel (PAGE) electrophoresis [10]. The pro-
teins were transferred to nitrocellulose sheets using an electroblotting
device (LKB Transphor, unit 2005) overnight at 35 V. The nitrocel-
lulose sheets were incubated in phosphate-bu¡ered saline (PBS) con-
taining 5% milk powder and 0.08% antifoam for 3 h at 37‡C. The
sheets were washed thrice with PBS containing 0.05% Tween 20 and
incubated in PBS containing 2.5% bovine serum albumin (BSA), 2.5%
normal horse serum, 0.05% Tween 20 and a⁄nity-puri¢ed (see Section
2.4) monoclonal anti-tat antibodies (clone C3.2D7). After an over-
night incubation at 4‡C the sheets were washed thrice with PBS con-
taining 0.05% Tween 20. The sheets were incubated in PBS containing
2.5% BSA, 2.5% normal horse serum, 0.05% Tween 20 and biotiny-
lated horse anti-mouse IgG (Vector, BA-2000, 1:1000) for 1 h at
37‡C. After washing thrice with PBS containing 0.05% Tween 20
the sheet were incubated in PBS containing 2.5% BSA, 2.5% normal
horse serum, 0.05% Tween 20 and horseradish peroxidase-avidin D
conjugate (Vector, A-2004, 1:1000) for 1 h at 37‡C. After the ¢nal
washing the sheets were developed at room temperature in phosphate
bu¡er (pH 7.4) containing 4-chloro-K-naphthol (0.75 mg/ml), metha-
nol (25%) and 0.12% solution of hydrogen peroxide (30%). The sheets
were washed twice with bidistilled water and air-dried.
2.6. Indian ink staining
The transfer membrane was washed twice with PBS containing
0.3% Tween 20. It was then immersed in PBS containing 0.3% Tween
20, 0.4% (v/v) Indian ink and placed on a shaking platform until
appearance of bands. The sheets were washed twice with bidistilled
water and air-dried.
3. Results
Our interest was to compare the e¡ects of Tat-IgG on the
intracellular and intercellular transactivation mediated by the
transactivator protein of HIV-1. For studying intracellular
transactivation Jurkat cells were co-transfected with a plasmid
expressing tat protein (pCV1) and another plasmid that con-
tained the construct HIV-1 LTR hybridized to the reporter
gene CAT (pC15CAT). For studying intercellular transactiva-
tion we transfected Jurkat cells separately with pCV1, or
pC15CAT, and cocultivated the two cell populations to ana-
lyze HIV-1 LTR transactivation.
The e¡ect of tat-IgG on the intracellular (Fig. 1A) and
intercellular (Fig. 1B) tat-mediated transactivation is depicted
in Fig. 1. Quantitatively the magnitude of transactivation
mediated by the intercellular tra⁄c of tat protein is only
22% of that of intracellular transactivation. These quantitative
di¡erences are probably due to the nature of the experimental
conditions in the two systems. Intercellular system is depend-
ent on the release and uptake of functionally active tat pro-
tein, whereas in the intracellular transactivation the tat pro-
tein functions within the same cell. This also explains the
di¡erences in the inhibitory e¡ects of tat IgG on intracellular
and intercellular transactivation systems. Since the immuno-
globulins cannot enter the cells, the intracellular transactiva-
tion is not signi¢cantly a¡ected by antibodies to tat protein
(Fig. 1A). However, the intercellular tra⁄c of tat protein can
be blocked by the capture of extracellular tat protein by tat-
speci¢c antibodies. This would result in the inhibition of in-
tercellular transactivation which is dependent on the availabil-
ity of functionally active extracellular tat protein. The immune
complexes formed between the extracellular tat protein and
tat IgG cannot be taken up by the cells. Fig. 1B depicts the
e¡ect of tat IgG on intercellular transactivation. At a concen-
tration of 7 Wg/ml of tat IgG, a 70% inhibition of intercellular
transactivation was achieved.
The second question we asked was whether the inhibition of
intercellular transactivation involves a speci¢c interaction be-
tween tat protein and tat IgG. To examine this aspect we
studied the e¡ect of di¡erent antibodies on the intercellular
transactivation mediated by the extracellular tat protein (Ta-
ble 1). Monoclonal antibodies to HIV-1 reverse transcriptase
at 7 Wg/ml had no e¡ect on the intercellular transactivation
potential of tat protein. Also the mAb to a human mammary
carcinoma protein did not a¡ect the transactivation potential
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Table 1
E¡ect of di¡erent monoclonal antibodies on the intercellular transactivation mediated by tat protein
Antibody used Antibody concentration (Wg/ml) pg CAT/10 Wg protein (% CAT activity)
^ 0 4519 (100)
HIV-1 RT IgG (4F8)a 7 4221 (93.4)
^ 0 2956 (100)
Ma-Ca IgG (C7C)b 7 2733 (92.4)
^ 0 4925 (100)
TAT IgG (C3.2.D7) 7 1445 (29.3)
aDesignates hybridoma clone 4F8 secreting antibodies to HIV-1 reverse transcriptase generated in our laboratory.
bDesignates hybridoma clone C7C secreting antibodies to a 80 kDa protein present only in human mammary tumor cells. This hybridoma clone
was generated in our laboratory.
Each value is the arithmetic mean of three individual experiments. The studies with individual antibodies were carried out at di¡erent times. For
this reason, the controls (without antibody) for each set of experiment are mentioned separately.
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of tat in this system. These results convey the message that
inhibition of intercellular transactivation by tat IgG involves a
speci¢c interaction between tat protein and the antibody. The
fact that anti-tat IgG reacts only with tat protein is further
supported by experiments on the immunoblotting of tat pro-
tein expressed in Jurkat cells (Fig. 2). Immunoreactivity of
anti-tat IgG with proteins separated by SDS-PAGE from Jur-
kat cells transfected with the tat-expressing plasmid pCV1
(lane 2) or non-transfected Jurkat cells (lane 1) is depicted
in Fig. 2B; lane 3 depicts the immunoreactive pro¢le of a
partially puri¢ed tat protein expressed in E. coli. The immu-
noreactive band at 14.5 kDa was observed only in lanes 2 and
3. There was no immunoreactive band detectable in proteins
separated from extracts of non-transfected Jurkat cells (lane
1).
Cultivation of Jurkat cells transfected with pC15CAT in
conditioned medium from cultured cells transfected with
pCV1 showed no transactivation potential (data not shown).
This would indicate that the tat protein released from cultured
cells is degraded during centrifugation and other experimental
manipulations. The fact that synthetic tat [12], recombinant
tat [13^15] and synthetic peptides corresponding to di¡erent
regions of the tat protein [16] are able to catalyze transacti-
vation in cells transfected with HIV-1 LTR-CAT indicates
that the transactivating potential of tat protein released
from the cell is independent of any tat binding protein, or
any cell-cell contact [17]. This conclusion is also supported
by studies on exogenous tat functions other than the trans-
activating potential [18,19].
4. Discussion
Tat protein is responsible for signals which induce a variety
of biological responses in HIV-infected cells, as well as in
uninfected cells. For this reason, tat protein is an attractive
target for therapeutic manipulation of HIV-1 infection. For
many years, attempts have been made in our laboratory to
develop compounds which block the transactivation potential
of tat protein [7,20^22]. This strategy is useful in combating
the dysregulation of infected cells in promoting large amounts
of virus replication. Extracellular tat protein, secreted by the
HIV-1-infected cells, is responsible for signalling dysregula-
tion of the metabolic machinery of uninfected cells leading
to immune suppression and T-cell apoptosis, a condition com-
monly found in patients with HIV-1 infection. In addition to
its immunologic dysregulation and apoptosis, tat protein in-
duces proliferation of AIDS-Kaposi’s sarcoma lesions. In a
recent study [23] we have shown a correlation of the antibody
status to tat protein in sera of HIV-infected asymptomatic
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Fig. 2. Immunoreactivity of anti-tat IgG with proteins separated by
SDS-PAGE: A: Indian ink staining. B: Immunoblot. Lane 1: non-
transfected Jurkat cells; lane 2: Jurkat cells transfected with the
tat-expressing plasmid pCV1; lane 3: partially puri¢ed tat protein
expressed in E. coli cells. Experimental details are described in Sec-
tion 2.
Fig. 1. E¡ect of anti-tat mAbs directed to the N-terminal region (2^
19) of tat protein on intracellular (A) and intercellular (B) transacti-
vation mediated by tat protein. All transfections were done in tripli-
cate for each set of experiments. The values depict an arithmetic
mean ( þ 8^14%) of three individual experiments.
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patients (n = 30) and HIV-infected patients with Kaposi’s sar-
coma lesions. HIV-infected patients with Kaposi’s sarcoma
(n = 36) did not possess IgG to tat protein. The fact that mono-
clonal antibodies to tat protein can abolish the intercellular
tra⁄c of transactivator, as evident from the data presented
here, can be applied to the concept of using tat protein for
AIDS vaccination. This approach is di¡erent from the known
vaccination strategies, since it is directed to a regulatory prod-
uct of the virus that is essential to pathogenesis rather than to
the virion itself. Using an inactivated but immunogenic tat
protein (tat toxoid) a phase 1 clinical trial on 14 asympto-
matic HIV-infected patients has recently been reported by
Gringeri et al. [24]. Although virologic parameters were not
assessed, they observed the production of anti-tat antibodies
and cell-mediated immunity in treated patients. We have re-
cently evaluated the anti-tat antibody status in 30 HIV-1-in-
fected asymptomatic individuals [20] and found that all the
asymptomatic patients had anti-tat IgG in their sera. Epitope
analysis has revealed that anti-tat antibodies in these sera
were directed towards the functional domains of tat protein.
In our opinion the application of anti-tat directed vaccines
will be more useful in pathological situations where the anti-
tat antibody titer is very low or absent. This is indeed the
situation in the later stage of HIV-1 infection, as well as in
AIDS patients with Kaposi’s sarcoma [23]. These are highly
immune-suppressed persons with very limited ability to syn-
thesize antibodies. For this reason, we suggest that passive
immunization with anti-tat antibodies is a useful approach
to abolish the signals mediated by the extracellular tat protein.
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